These results suggests that the ErbB family of proteins might play a role in infigratinib resistance and that varlitinib would be more effective in FGFR-driven HCC, in which higher levels of p-ErbB2 and/or p-ErbB3 are expressed. Here, ERBB3 is linked to hepatocellular carcinoma.